Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 1 mg - tablet, film coated - excipient ingredients: hypromellose; crospovidone; lactose monohydrate; hyprolose; sodium lauryl sulfate; microcrystalline cellulose; magnesium stearate; propylene glycol; titanium dioxide; iron oxide yellow - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 2 mg - tablet, film coated - excipient ingredients: titanium dioxide; hypromellose; sodium lauryl sulfate; hyprolose; magnesium stearate; lactose monohydrate; iron oxide red; iron oxide yellow; microcrystalline cellulose; propylene glycol; crospovidone - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 1.5 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; propylene glycol; microcrystalline cellulose; hypromellose; magnesium stearate; titanium dioxide; crospovidone; hyprolose; iron oxide yellow - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 2.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium lauryl sulfate; hypromellose; titanium dioxide; crospovidone; propylene glycol; lactose monohydrate; iron oxide red; microcrystalline cellulose; iron oxide yellow; hyprolose - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 0.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; magnesium stearate; propylene glycol; crospovidone; titanium dioxide; hyprolose; lactose monohydrate; sodium lauryl sulfate - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Malta - English - Medicines Authority

hualan pharmaceuticals limited 16/17 college green dublin d02 v078 , ireland - tablet - lorazepam 0.25 mg - psycholeptics

Malta - English - Medicines Authority

hualan pharmaceuticals limited 16/17 college green dublin d02 v078 , ireland - tablet - lorazepam 0.5 mg - psycholeptics

Malta - English - Medicines Authority

hualan pharmaceuticals limited 16/17 college green dublin d02 v078 , ireland - tablet - lorazepam 1 mg - psycholeptics

Malta - English - Medicines Authority

hualan pharmaceuticals limited 16/17 college green dublin d02 v078 , ireland - tablet - lorazepam 2.51 mg - psycholeptics

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lorazepam, quantity: 2.5 mg - tablet - excipient ingredients: iron oxide yellow; lactose monohydrate; magnesium stearate; microcrystalline cellulose; quinoline yellow; polacrilin potassium